217 related articles for article (PubMed ID: 21526620)
1. Antiretroviral drug resistance--implications for HIV/AIDS reduction in sub-Saharan Africa and other developing countries.
Obiako OR; Murktar HM; Ogoina D
Niger J Med; 2010; 19(4):352-60. PubMed ID: 21526620
[TBL] [Abstract][Full Text] [Related]
2. Antiretroviral drug resistance--implications for HIV/AIDS reduction in sub-Saharan Africa and other developing countries.
Obiako OR; Murktar HM; Ogoina D
Niger J Med; 2010; 19(3):302-10. PubMed ID: 20845636
[TBL] [Abstract][Full Text] [Related]
3. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
Van Vaerenbergh K
Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
[TBL] [Abstract][Full Text] [Related]
4. The status of HIV-1 resistance to antiretroviral drugs in sub-Saharan Africa.
Hamers RL; Derdelinckx I; van Vugt M; Stevens W; Rinke de Wit TF; Schuurman R;
Antivir Ther; 2008; 13(5):625-39. PubMed ID: 18771046
[TBL] [Abstract][Full Text] [Related]
5. HIV antiretroviral drug resistance in Africa.
Nkengasong JN; Adje-Toure C; Weidle PJ
AIDS Rev; 2004; 6(1):4-12. PubMed ID: 15168736
[TBL] [Abstract][Full Text] [Related]
6. The impact of HIV-1 subtype on the clinical response on HAART.
Frater J
J HIV Ther; 2002 Nov; 7(4):92-6. PubMed ID: 12733607
[TBL] [Abstract][Full Text] [Related]
7. Characterization of drug-resistance mutations in HIV-1 isolates from non-HAART and HAART treated patients in Burkina Faso.
Nadembega WM; Giannella S; Simpore J; Ceccherini-Silberstein F; Pietra V; Bertoli A; Pignatelli S; Bellocchi MC; Nikiema JB; Cappelli G; Bere A; Colizzi V; Perno CP; Musumeci S
J Med Virol; 2006 Nov; 78(11):1385-91. PubMed ID: 16998878
[TBL] [Abstract][Full Text] [Related]
8. Genotypic resistance tests for the management of the HIV-infected patient with non-B viral isolates.
Visco-Comandini U; Balotta C
Scand J Infect Dis Suppl; 2003; 106():75-8. PubMed ID: 15000590
[TBL] [Abstract][Full Text] [Related]
9. Persistence of HIV-1 drug resistance mutations and emergence during antiretroviral treatment interruption: considerations from a clinical case.
Torti C; Moretti F; Uccelli MC; Tirelli V; Quiros-Roldan E; Gargiulo F; Carosi G
Med Sci Monit; 2003 Apr; 9(4):CS16-9. PubMed ID: 12709675
[TBL] [Abstract][Full Text] [Related]
10. Drug resistance in non-subtype B HIV-1.
Kantor R; Katzenstein D
J Clin Virol; 2004 Mar; 29(3):152-9. PubMed ID: 14962783
[TBL] [Abstract][Full Text] [Related]
11. Impact of HIV-1 pol diversity on drug resistance and its clinical implications.
Kantor R
Curr Opin Infect Dis; 2006 Dec; 19(6):594-606. PubMed ID: 17075337
[TBL] [Abstract][Full Text] [Related]
12. Temporal changes in the epidemiology of transmission of drug-resistant HIV-1 across the world.
Frentz D; Boucher CA; van de Vijver DA
AIDS Rev; 2012; 14(1):17-27. PubMed ID: 22297501
[TBL] [Abstract][Full Text] [Related]
13. Genotypic resistance profiles in antiretroviral-naive HIV-1 infections before and after initiation of first-line HAART: impact of polymorphism on resistance to therapy.
Sukasem C; Churdboonchart V; Sukeepaisarncharoen W; Piroj W; Inwisai T; Tiensuwan M; Chantratita W
Int J Antimicrob Agents; 2008 Mar; 31(3):277-81. PubMed ID: 18182278
[TBL] [Abstract][Full Text] [Related]
14. Drug resistance among chronic HIV-1-infected patients naïve for use of anti-retroviral therapy in Sao Paulo city.
Gonsalez CR; Alcalde R; Nishiya A; Barreto CC; Silva FE; de Almeida A; Mendonça M; Ferreira F; Fernandes SS; Casseb J; Duarte AJ
Virus Res; 2007 Nov; 129(2):87-90. PubMed ID: 17686543
[TBL] [Abstract][Full Text] [Related]
15. The dual role of pharmacogenetics in HIV treatment: mutations and polymorphisms regulating antiretroviral drug resistance and disposition.
Michaud V; Bar-Magen T; Turgeon J; Flockhart D; Desta Z; Wainberg MA
Pharmacol Rev; 2012 Jul; 64(3):803-33. PubMed ID: 22759796
[TBL] [Abstract][Full Text] [Related]
16. Antiretroviral drug resistance testing in adult HIV-1 infection: 2008 recommendations of an International AIDS Society-USA panel.
Hirsch MS; Günthard HF; Schapiro JM; Brun-Vézinet F; Clotet B; Hammer SM; Johnson VA; Kuritzkes DR; Mellors JW; Pillay D; Yeni PG; Jacobsen DM; Richman DD
Clin Infect Dis; 2008 Jul; 47(2):266-85. PubMed ID: 18549313
[TBL] [Abstract][Full Text] [Related]
17. Genotypic resistance and HIV-1 subtype in Brazilian children on dual and triple combination therapy.
Machado ES; Lambert JS; Watson DC; Afonso AO; da Cunha SM; Nogueira SA; Caride E; Oliveira RH; Sill AM; DeVico A; Tanuri A
J Clin Virol; 2004 May; 30(1):24-31. PubMed ID: 15072750
[TBL] [Abstract][Full Text] [Related]
18. Polymorphism in HIV-1 non-subtype B protease and reverse transcriptase and its potential impact on drug susceptibility and drug resistance evolution.
Kantor R; Katzenstein D
AIDS Rev; 2003; 5(1):25-35. PubMed ID: 12875105
[TBL] [Abstract][Full Text] [Related]
19. [AIDS treatment in Africa: the risk of antiretroviral resistance].
Hamers RL; Schuurman R; van Vugt M; Derdelinckx I; Rinke de Wit TF
Ned Tijdschr Geneeskd; 2007 Dec; 151(48):2666-71. PubMed ID: 18179083
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of an in-house genotyping resistance test for HIV-1 drug resistance interpretation and genotyping.
Chen JH; Wong KH; Chan K; Lam HY; Lee SS; Li P; Lee MP; Tsang DN; Zheng BJ; Yuen KY; Yam WC
J Clin Virol; 2007 Jun; 39(2):125-31. PubMed ID: 17449318
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
